a disubstituted succinyl caprolactam hydroxymate mmp3inhibitor

A Disubstituted Succinyl Caprolactam Hydroxymate Mmp3inhibitor is an experimental small molecule inhibitor designed to target matrix metalloproteinase 3 (MMP‑3, also known as stromelysin‑1). It features a hydroxamate group that chelates the catalytic zinc ion in the active site of MMPs, thereby inhibiting their proteolytic activity. This compound belongs to a class of broad-spectrum matrix metalloproteinase inhibitors with structural modifications intended to enhance selectivity and potency against MMP‑1, MMP‑2, and especially MMP‑3. It has not been approved for clinical use and remains at the experimental stage[1][4][7].

Other names

A Disubstituted Succinyl Caprolactam Hydroxymate Mmp3inhibitor(2S,3R)-N-hydroxy-2-(3-hydroxypropyl)-N'-[(3S)-1-(2-methoxyethyl)-2-oxoazepan-3-yl]-3-(2-methylpropyl)butanediamide(2S,3R)-N-hydroxy-2-(3-hydroxypropyl)-N'-((3S)-1-(2-methoxyethyl)-2-oxoazepan-3-yl)-3-(2-methylpropyl)butanediamideDB02090DB-02090DB 02090PD008563PD-008563PD 008563NS00072007NS-00072007NS 00072007